Jackson Creek Investment Advisors LLC Invests $1.46 Million in CareDx, Inc (NASDAQ:CDNA)

Jackson Creek Investment Advisors LLC bought a new position in shares of CareDx, Inc (NASDAQ:CDNA) in the fourth quarter, Holdings Channel reports. The institutional investor bought 121,229 shares of the company’s stock, valued at approximately $1,455,000. CareDx accounts for approximately 0.6% of Jackson Creek Investment Advisors LLC’s investment portfolio, making the stock its 14th largest position.

Other institutional investors have also recently added to or reduced their stakes in the company. Citigroup Inc. grew its stake in CareDx by 7.1% during the third quarter. Citigroup Inc. now owns 132,560 shares of the company’s stock worth $928,000 after buying an additional 8,768 shares during the last quarter. ARK Investment Management LLC boosted its holdings in shares of CareDx by 7.7% in the 4th quarter. ARK Investment Management LLC now owns 7,194,722 shares of the company’s stock worth $86,337,000 after acquiring an additional 515,399 shares in the last quarter. First Eagle Investment Management LLC grew its position in CareDx by 38.7% during the 3rd quarter. First Eagle Investment Management LLC now owns 1,005,189 shares of the company’s stock worth $7,036,000 after acquiring an additional 280,345 shares during the last quarter. Swiss National Bank increased its holdings in CareDx by 2.3% during the 3rd quarter. Swiss National Bank now owns 118,200 shares of the company’s stock valued at $827,000 after purchasing an additional 2,700 shares in the last quarter. Finally, Vanguard Group Inc. raised its position in CareDx by 1.2% in the 3rd quarter. Vanguard Group Inc. now owns 4,138,591 shares of the company’s stock valued at $28,970,000 after purchasing an additional 50,667 shares during the last quarter.

Wall Street Analysts Forecast Growth

Separately, Stephens restated an “overweight” rating and set a $15.00 target price on shares of CareDx in a report on Wednesday, April 17th. Three analysts have rated the stock with a hold rating and two have given a buy rating to the company. According to MarketBeat.com, CareDx currently has a consensus rating of “Hold” and an average target price of $13.50.

CareDx Price Performance

Shares of CDNA stock traded down $0.44 during trading hours on Tuesday, reaching $7.76. 825,590 shares of the company were exchanged, compared to its average volume of 885,470. CareDx, Inc has a fifty-two week low of $4.80 and a fifty-two week high of $12.93. The stock’s fifty day moving average is $9.61 and its two-hundred day moving average is $9.27. The company has a market cap of $401.81 million, a price-to-earnings ratio of -2.32 and a beta of 1.42.

CareDx (NASDAQ:CDNA) last posted its quarterly earnings data on Wednesday, February 28th. The company reported ($2.21) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.24) by ($1.97). The firm had revenue of $65.57 million for the quarter, compared to analyst estimates of $63.66 million. CareDx had a negative return on equity of 51.40% and a negative net margin of 67.88%. The firm’s quarterly revenue was down 20.4% compared to the same quarter last year. During the same period in the prior year, the company posted ($0.34) EPS. On average, research analysts anticipate that CareDx, Inc will post -1.59 earnings per share for the current year.

CareDx Company Profile

CareDx, Inc engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients.